co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
Pinwheel Therapeutics is working an one-of-its kind anticoagulant reversal agent Ciraparantag.The 108 BioCapital fund, which has initiated the process to set up a GIFT City feeder vehicle, is backed by a roster of prominent investors
Thakur pointed to pharmaceuticals as a sector where both domestic investment and foreign inflows could pick up, possibly as early as the next financial year.
Pharma stocks gained after Budget 2026 announced a Rs 10,000 crore Biopharma Shakti initiative.
Tax certainty, customs duty relief and healthcare infra push shape industry outlook
The move would dismantle the existing system under which bulk drugs and finished formulations operate under a common licence
The firm remains bullish on single-specialty platforms, medical devices, digital health, and consumer healthcare, expecting India to absorb a significant share of its billion-dollar fund
Multinational pharmaceutical companies are making billions in India but investing almost nothing in R&D here — treating the world's fastest-growing pharma market as a sales territory, not an innovation hub
Distribution collaboration with Eli Lilly for Mounjaro is a key factor to watch
Investors will watch for management commentary on the US recovery outlook, particularly around the uptake of Lanreotide and Abraxane, and progress on the complex generics and peptide portfolio.
The company plans to launch the injectable version of Semaglutide in a number of countries, starting with Canada in January 2026. India and Brazil will follow
Dr Reddy's Laboratories Q2 FY26 results: Dr Reddy's declares fiscal second quarter results; check net profit, revenue, margin, other details.
The CDMO business for small molecules grew 58 percent YoY in Q2FY26, helped by a ramp-up in sales from new manufacturing assets
The directive is similar to the one issued after India-made cough syrups were blamed for deaths of children in Gambia and Uzbekistan even as Coldrif toll climbs to 22 after two more children die
While inviting applications, the Department of Pharmaceuticals has notified amendments to the scheme and issued revised guidelines to enhance the impact of the scheme and make it better suited to address the requirements of all stakeholders.
At close, the Nifty Pharma index was lower by 2.14 percent and 5.2 percent for the week, with most constituents in the red.
Malladi Drugs raised Rs 250 crore from healthcare and pharma focused private equity fund InvAscent. The PE fund holds around 22-23% stake in the company
For Moneycontrol Pro Panorama September 16 edition: Indian markets could be overestimating US Fed rate cut impact, equity tag for REITs a step towards global best practices, transformation of digital revolution and the road ahead, India’s growing influence in global diplomacy, and more
NPPA directs firms to issue revised price lists instead of recalling stock; compliance to be ensured at retailer level
Rates have been pruned for drugs used in chronic diseases as also medical devices and hospital chains
Labour-intensive exports to the US are expected to take the hardest hit as these sectors will face a rate of more than 50 percent given that Trump’s reciprocal tariffs are over and above the most favoured nation (MFN) duties in place.
India's duties on chemicals and pharmaceuticals are mostly in the range of 0-10 percent, with many pharmaceuticals at zero tariffs.
Sun Pharma’s top line growth is steady. Innovative medicines to act as growth tonic, as the US generics business remains soft. The stock valuation is justified.
Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors
The company has a CDMO pipeline of 90+ human health projects, wherein 15 products are commercialised, targeting APIs and intermediates
Reduced contribution of Revlimid is likely to get offset by new products
